SG Americas Securities LLC Increases Stake in Surmodics, Inc. (NASDAQ:SRDX)

SG Americas Securities LLC grew its stake in Surmodics, Inc. (NASDAQ:SRDX) by 22.1% during the 4th quarter, HoldingsChannel reports. The firm owned 6,940 shares of the company’s stock after buying an additional 1,255 shares during the quarter. SG Americas Securities LLC’s holdings in Surmodics were worth $275,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in SRDX. State Street Corp boosted its holdings in Surmodics by 19.2% during the third quarter. State Street Corp now owns 374,068 shares of the company’s stock worth $14,506,000 after buying an additional 60,240 shares in the last quarter. Oddo BHF Asset Management Sas purchased a new stake in shares of Surmodics during the 3rd quarter worth about $6,593,000. Charles Schwab Investment Management Inc. grew its position in shares of Surmodics by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 116,311 shares of the company’s stock valued at $4,511,000 after acquiring an additional 1,491 shares during the period. Barclays PLC increased its stake in shares of Surmodics by 16.0% in the 3rd quarter. Barclays PLC now owns 88,750 shares of the company’s stock valued at $3,443,000 after purchasing an additional 12,271 shares in the last quarter. Finally, Phocas Financial Corp. acquired a new position in Surmodics in the 3rd quarter worth about $3,430,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

Insider Transactions at Surmodics

In related news, CFO Timothy J. Arens sold 7,009 shares of Surmodics stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now owns 70,350 shares in the company, valued at approximately $2,774,604. This trade represents a 9.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 8.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on SRDX. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a report on Thursday, January 30th. StockNews.com started coverage on shares of Surmodics in a research note on Monday. They issued a “hold” rating on the stock. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, Surmodics has an average rating of “Hold” and an average price target of $50.00.

Surmodics Price Performance

Shares of Surmodics stock opened at $33.85 on Thursday. The stock has a market capitalization of $484.06 million, a P/E ratio of -33.51 and a beta of 1.20. The business has a 50 day simple moving average of $38.36 and a two-hundred day simple moving average of $38.97. Surmodics, Inc. has a 12 month low of $25.17 and a 12 month high of $42.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. As a group, analysts predict that Surmodics, Inc. will post 0.19 EPS for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).